Pharmaceuticals, Biotechnology and Life Sciences
Novartis was cleared on Thursday by the US Food and Drug Administration (FDA) for combination of Tafinlar (dabrafenib) with Mekinist (trametinib) for treating metastatic non-small cell lung cancer (NSCLC) in patients whose tumors express the BRAF V600E mutation, which is fourth actionable genomic biomaker in metastatic NSCLC
Ceylad said on Monday that it’s gotten promising early clinical results at the 3-month follow-up of the first dose-level in the solid tumor arm of the THINK trial (THerapeutic Immunotherapy with CAR-T NKR-2).
South Africa’s competition watchdog has launched an investigation into three drug companies accused of over-charging for cancer medicines, the agency’s chief said on Tuesday.
The U.S. Food and Drug Administration on Tuesday approved Merck’s Keytruda as a first cancer treatment for any solid tumor with a specific genetic feature.
Genomic Vision, a company specialized in the development of diagnostic tests (IVD) for the early detection of cancers and genetic diseases and applications for life sciences research (LSR), have entered into a technological collaboration with AstraZeneca in the field of targeting DNA damage response (DDR) for novel anti-cancer treatments strategy.
The U.S. Food and Drug Administration today posted warning letters addressed to 14 U.S.-based companies illegally selling more than 65 products that fraudulently claim to prevent, diagnose, treat or cure cancer.
Tiziana Life Sciences a cancer drugs making focused clinical stage biotechnology company got approval in Israel to start testing inhibitor of cell cycle dependent kinases (CDKs), milciclib in a phase II clinical trial.
Faron Pharmaceuticals and the University of Birmingham Medical School, have signed an agreement to begin a liver cancer program for clinical testing of Faron’s immuno switch antibody Clevegen.
Sosei Group Corporation’s subsidiary Heptares Therapeutics got milestone payment from AstraZeneca for working together on an immuno-oncology project.
Bristol-Myers Squibb and Incyte Corporation will evaluate combination of epacadostat with Opdivo in advancing a clinical development program into phase 3 registrational trials in first-line non-small cell lung cancer across the spectrum of PD-L1 expression and first-line head and neck cancer in 2017.